<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">The viricidal activity in-vitro of topical and oral PVP‐I products against SARS‐CoV‐2 was recently reported (
 <xref rid="bib10" ref-type="bibr">Bidra et al., 2020</xref>). All four products (antiseptic solution, PVP-I at 10%; skin cleanser, PVP-I at 7.5%; gargle and mouth wash, PVP-I at 1%; and throat spray, PVP-I at 0.45%) achieved ≥ 99.99% viricidal activity against SARS-CoV-2 within 30 seconds of being in contact with the virus (
 <xref rid="bib10" ref-type="bibr">Bidra et al., 2020</xref>). The use of 0.5% PVP-I was proposed among healthcare workers and their patients to minimize the risk of the spread of COVID-19 in addition to the recommended IPC measures and PPE. A mouthwash or nasal spray containing PVP-I may be an effective strategy both to combat the virus at its point of entry and to reduce SARS-CoV-2 transmission through its droplet emission from the mouth
</p>
